Oppenheimer raised the firm’s price target on DexCom (DXCM) to $102 from $95 and keeps an Outperform rating on the shares following quarterly results. The firm notes revenue guide was raised to $4.6B-$4.625B. Oppenheimer believes management is choosing to stay conservative with the raise. DexCom announced that CEO Kevin Sayer will retire at the end of 2025, with President and COO Jake Leach assuming the role. Sayer will remain executive chairman. The firm expects a smooth transition.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM:
- Dexcom’s Strong Financial Performance and Growth Prospects Justify Buy Rating
- Dexcom Reports Strong Q2 2025 Growth and Leadership Change
- Dexcom’s Strong Financial Performance and Strategic Positioning Justify Buy Rating
- Closing Bell Movers: Microsoft jumps 9%, Meta up 12% on earnings beats
- Dexcom Announces Leadership Transition with New CEO